Research Briefs: Updates From EndoGastric Solutions, Cordis, Aptus Endosystems
This article was originally published in The Gray Sheet
Executive Summary
RESPECT trial is designed to provide the kind of Level 1 evidence EndoGastic Solutions needs to persuade payers and physicians of the benefits of the EsophyX GERD-repair device. Cordis and Aptus Endosystems release new data at the Vascular Interventional Advances (VIVA) 2013 annual meeting in Las Vegas.
You may also be interested in...
Transoral GERD Devices: Riding Out The Road To Reimbursement
With health care becoming increasingly data driven, third-party payors are requiring a higher level of evidence before making a positive coverage determination for a new technology or procedure. This has made the road to reimbursement much longer and tougher for device companies in general, and manufacturers of transoral devices for GERD are a prime example.
EVAR Update: Competitors Stake Their Ground In A High-Growth Space
The endovascular abdominal aortic aneurysm repair (EVAR) market is one of the brightest growth opportunities in the medical device arena today. As a result, the competitive landscape is heating up as several new entrants stake their claim for a share of this $1+ billion opportunity.
News In Brief
Caution on robotic surgery from Ob/Gyn group. FDA gets closer to gaining access to most of fiscal 2013 user fees. More news.